JP2017503511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503511A5 JP2017503511A5 JP2016545971A JP2016545971A JP2017503511A5 JP 2017503511 A5 JP2017503511 A5 JP 2017503511A5 JP 2016545971 A JP2016545971 A JP 2016545971A JP 2016545971 A JP2016545971 A JP 2016545971A JP 2017503511 A5 JP2017503511 A5 JP 2017503511A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461926865P | 2014-01-13 | 2014-01-13 | |
| US201461926863P | 2014-01-13 | 2014-01-13 | |
| US61/926,863 | 2014-01-13 | ||
| US61/926,865 | 2014-01-13 | ||
| US201462042771P | 2014-08-27 | 2014-08-27 | |
| US201462042755P | 2014-08-27 | 2014-08-27 | |
| US62/042,755 | 2014-08-27 | ||
| US62/042,771 | 2014-08-27 | ||
| PCT/US2015/011269 WO2015106290A1 (en) | 2014-01-13 | 2015-01-13 | Internalizing moieties |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020029459A Division JP2020096636A (ja) | 2014-01-13 | 2020-02-25 | 内在化部分 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503511A JP2017503511A (ja) | 2017-02-02 |
| JP2017503511A5 true JP2017503511A5 (https=) | 2018-02-15 |
| JP6709733B2 JP6709733B2 (ja) | 2020-06-17 |
Family
ID=53524430
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545971A Expired - Fee Related JP6709733B2 (ja) | 2014-01-13 | 2015-01-13 | 内在化部分 |
| JP2020029459A Pending JP2020096636A (ja) | 2014-01-13 | 2020-02-25 | 内在化部分 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020029459A Pending JP2020096636A (ja) | 2014-01-13 | 2020-02-25 | 内在化部分 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10221250B2 (https=) |
| EP (2) | EP3094646B1 (https=) |
| JP (2) | JP6709733B2 (https=) |
| AU (1) | AU2015204446A1 (https=) |
| CA (1) | CA2936102A1 (https=) |
| HK (1) | HK1231492A1 (https=) |
| WO (1) | WO2015106290A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6178785B2 (ja) | 2011-04-01 | 2017-08-09 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ | 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用 |
| CA2907072A1 (en) | 2012-03-16 | 2013-09-19 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of dmpk |
| AU2014218854B2 (en) | 2013-02-20 | 2019-01-24 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
| AU2015204446A1 (en) | 2014-01-13 | 2016-07-14 | Valerion Therapeutics, Llc | Internalizing moieties |
| US10040867B2 (en) | 2014-03-04 | 2018-08-07 | Yale University | Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations |
| US10238742B2 (en) | 2014-06-25 | 2019-03-26 | Yale University | Cell penetrating nucleolytic antibody based cancer therapy |
| CA2995673A1 (en) * | 2014-08-27 | 2016-03-03 | Valerion Therapeutics, Llc | Internalizing moieties for treatment of cancer |
| EP3471777A1 (en) | 2016-06-15 | 2019-04-24 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
| WO2017218824A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| JP2019535645A (ja) * | 2016-09-09 | 2019-12-12 | バレリオン セラピューティクス， エルエルシー | ラフォラ病の処置のための方法及び組成物 |
| KR102698752B1 (ko) * | 2017-03-20 | 2024-08-26 | 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 | 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체 |
| EP3655432A4 (en) * | 2017-07-17 | 2021-04-14 | Nucleus Therapeutics Pty Ltd | BINDING PROTEINS 1 |
| US20210137960A1 (en) | 2018-02-01 | 2021-05-13 | Yale University | Compositions and methods for inhibition of nuclear-penetrating antibodies |
| EP3765062A4 (en) * | 2018-03-15 | 2022-04-13 | Valerion Therapeutics, LLC | METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYGLUCOUS DISORDERS |
| CA3111186A1 (en) | 2018-08-31 | 2020-03-05 | Yale University | Compositions and methods for enhancing triplex and nuclease-based gene editing |
| EP3844287B1 (en) | 2018-08-31 | 2024-05-22 | Yale University | Compositions and methods for enhancing donor oligonucleotide-based gene editing |
| US20210340279A1 (en) * | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2021042060A1 (en) * | 2019-08-30 | 2021-03-04 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
| WO2021077070A1 (en) | 2019-10-18 | 2021-04-22 | Yale University | Compositions and methods for inhibition of cell-penetrating antibodies |
| CN116529266A (zh) | 2020-08-31 | 2023-08-01 | 耶鲁大学 | 用于将核酸递送到细胞的组合物和方法 |
| CN117295753A (zh) | 2020-12-04 | 2023-12-26 | 基那奥生物公司 | 用于将核酸递送到细胞的组合物和方法 |
| AU2022228255A1 (en) | 2021-03-03 | 2023-09-28 | Yale University | Compositions and methods for treating skeletal muscle disease |
| AU2022302143A1 (en) | 2021-07-02 | 2024-01-18 | Yale University | Compositions and methods for treating cancers |
| EP4395832A1 (en) | 2021-08-31 | 2024-07-10 | Yale University | Compositions and methods for treating cancers |
| WO2023168401A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for treating disease |
| WO2023168427A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
| US20230303719A1 (en) * | 2022-03-03 | 2023-09-28 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
| AU2023338626A1 (en) | 2022-09-09 | 2025-03-20 | Yale University | Proteolysis targeting antibodies and methods of use thereof |
| EP4642488A1 (en) | 2022-12-27 | 2025-11-05 | Yale University | Antibody drug conjugates |
| WO2024158824A1 (en) | 2023-01-23 | 2024-08-02 | Yale University | Antibody oligonucleotide conjugates |
| EP4683674A1 (en) | 2023-03-23 | 2026-01-28 | Yale University | Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping |
| EP4727979A2 (en) * | 2023-06-15 | 2026-04-22 | Caris Science, Inc. | Compositions and methods for targeting extracellular dna |
| WO2025049905A1 (en) | 2023-09-01 | 2025-03-06 | Gennao Bio, Inc. | Dnase co-expression in host cells |
| WO2025097000A1 (en) | 2023-11-01 | 2025-05-08 | Yale University | Antibody-based methods for treating polycystic kidney disease |
| WO2026011073A1 (en) * | 2024-07-03 | 2026-01-08 | Yale University | Antibody drug conjugates |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| JP2000507225A (ja) * | 1996-03-08 | 2000-06-13 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | ｍａｂ ３Ｅ１０ ならびにその突然変異体および／または機能性フラグメントを使用する送達システム |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| AU2008207948A1 (en) | 2007-01-22 | 2008-07-31 | The United States Government As Represented By The Department Of Veterans Affairs | Use of antibody conjugates |
| EP3486653A1 (en) | 2007-05-24 | 2019-05-22 | The United States Government as represented by The Department of Veterans Affairs | Treatment of skeletal muscle disorder using ent2 |
| WO2010044894A1 (en) | 2008-10-15 | 2010-04-22 | 4S3 Bioscience Inc. | Methods and compositions for treatment of myotonic dystrophy |
| AU2010260145B2 (en) | 2009-06-15 | 2015-08-20 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides |
| GB2476671B (en) | 2010-01-04 | 2014-11-26 | Plastic Logic Ltd | Touch-sensing systems |
| JP5240316B2 (ja) | 2010-10-26 | 2013-07-17 | 株式会社デンソー | 車両乗員非操作運転システム |
| WO2012145125A1 (en) | 2011-03-25 | 2012-10-26 | 4S3 Bioscience Inc. | Targeted radionuclides |
| JP6178785B2 (ja) * | 2011-04-01 | 2017-08-09 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ | 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用 |
| WO2012138733A2 (en) | 2011-04-05 | 2012-10-11 | Chevron Oronite Company Llc | Low viscosity marine cylinder lubricating oil compositions |
| CA2907072A1 (en) | 2012-03-16 | 2013-09-19 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of dmpk |
| US9283272B2 (en) * | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| WO2013177428A1 (en) * | 2012-05-23 | 2013-11-28 | Valerion Therapeutics, Inc. | Methods for increasing muscle contractility |
| WO2014130722A1 (en) | 2013-02-20 | 2014-08-28 | Valerion Therapeutics, Llc | Methods and compositions for treatment of forbes-cori disease |
| AU2014218854B2 (en) | 2013-02-20 | 2019-01-24 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
| AU2015204446A1 (en) | 2014-01-13 | 2016-07-14 | Valerion Therapeutics, Llc | Internalizing moieties |
| WO2015192092A1 (en) | 2014-06-13 | 2015-12-17 | Valerion Therapeutics, Llc | Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders |
| CA2995673A1 (en) | 2014-08-27 | 2016-03-03 | Valerion Therapeutics, Llc | Internalizing moieties for treatment of cancer |
-
2015
- 2015-01-13 AU AU2015204446A patent/AU2015204446A1/en not_active Abandoned
- 2015-01-13 EP EP15735467.1A patent/EP3094646B1/en not_active Not-in-force
- 2015-01-13 CA CA2936102A patent/CA2936102A1/en not_active Abandoned
- 2015-01-13 HK HK17105169.5A patent/HK1231492A1/zh unknown
- 2015-01-13 WO PCT/US2015/011269 patent/WO2015106290A1/en not_active Ceased
- 2015-01-13 EP EP20169442.9A patent/EP3711820A1/en not_active Withdrawn
- 2015-01-13 JP JP2016545971A patent/JP6709733B2/ja not_active Expired - Fee Related
- 2015-01-13 US US15/111,160 patent/US10221250B2/en active Active
-
2019
- 2019-03-04 US US16/291,896 patent/US10703824B2/en active Active
-
2020
- 2020-02-25 JP JP2020029459A patent/JP2020096636A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503511A5 (https=) | ||
| JP6978468B2 (ja) | Ｖｅｇｆを阻害する安定かつ可溶性の抗体 | |
| JP7577435B2 (ja) | Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト | |
| JP6910380B2 (ja) | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 | |
| KR101523788B1 (ko) | 뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조 | |
| JP4845732B2 (ja) | 抗ｖｅｇｆ抗体 | |
| JP6726168B2 (ja) | Ｃｄｈ１９およびｃｄ３に対する抗体コンストラクト | |
| JP7671326B2 (ja) | 抗フリズルド抗体及び使用方法 | |
| JP5738294B2 (ja) | 抗ｖｅｇｆモノクローナル抗体およびその抗体を含む薬学的組成物 | |
| JP5823858B2 (ja) | 抗ｖｅｇｆ抗体 | |
| KR20200074201A (ko) | Alk-1 및 bmpr-2에 결합하는 이중특이적 항체 | |
| JP6328231B2 (ja) | 抗ｖｅｇｆ抗体およびそれを含む癌または血管新生関連疾患を予防、診断、または治療するための医薬組成物 | |
| TWI685502B (zh) | 新穎抗人類Ｔｉｅ２抗體 | |
| CN112566940A (zh) | 多特异性wnt替代分子和其用途 | |
| JP2020510658A (ja) | 操作されたヘテロ二量体タンパク質 | |
| NO345763B1 (no) | Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering. | |
| MX2014009565A (es) | Anticuerpos monocatenarios y otros heteromultimeros. | |
| CN116323671A (zh) | 具有增加的选择性的多靶向性双特异性抗原结合分子 | |
| KR20200105493A (ko) | Muc17 및 cd3에 대한 이중특이적 항체 구축물 | |
| KR20220082007A (ko) | 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도 | |
| CN116249547B (zh) | 脑特异性血管生成抑制剂1(bai1)抗体及其用途 | |
| JPWO2019124461A1 (ja) | 抗体断片多量体分子、医薬品、抗腫瘍剤、自己免疫疾患治療剤及び抗体断片多量体分子の作製方法 | |
| HK40073145A (en) | Antibodies against the poliovirus receptor (pvr) and uses thereof | |
| CN115819605A (zh) | 一种连接抗体的抗原结合功能域的方法及其应用 | |
| HK40073145B (zh) | 针对脊髓灰质炎病毒受体(pvr)的抗体及其用途 |